

**THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION**  
**PATIENT INFORMATION LEAFLET**  
**FOR THE MEDICINAL PRODUCT**  
**Grippol® Quadrivalent**  
**Vaccine against influenza quadrivalent inactivated subunit adjuvant**

**Marketing Authorization:****Trade name:** Grippol® Quadrivalent

Vaccine against influenza quadrivalent inactivated subunit adjuvant

**Group name:** Vaccine against influenza [inactivated] + Azoximer bromide.**Dosage form:** solution for intramuscular and subcutaneous injection.**Composition per 1 dose (0.5 ml):***Active ingredients:*

Serotype A (H <sub>1</sub> N <sub>1</sub> )* influenza virus antigen with concentration of hemagglutinin	- 5 µg
Serotype A (H <sub>3</sub> N <sub>2</sub> )* influenza virus antigen with concentration of hemagglutinin	- 5 µg
Type B influenza virus antigen (Yamagata line)* with concentration of hemagglutinin	- 5 µg
Type B influenza virus antigen (Victoria line)* with concentration of hemagglutinin	- 5 µg
Polyoxidonium®, freeze-dried substance** (Azoximer bromide).	- 500 µg

*Excipients:*

PBS - phosphate-buffered saline	up to 0.5 mL
Thimerosal ***	50 µg

\* - strains of influenza virus antigen - in accordance with the guidelines of WHO for the current epidemic season for the Northern hemisphere;

\*\* - equivalent to active ingredient Azoximer bromide, excipients - mannitol, povidone;

\*\*\* - preservative thiomersal - only for multidose vial (10 doses - 5 mL in vial).

Notes:

1. The composition of phosphate-buffered saline includes: potassium chloride, potassium dihydrogen phosphate, sodium chloride, water for injection.
2. Triton X-100 may also present in influenza virus antigens as an excipient.

### **Appearance**

Colorless or white off slightly opalescent fluid.

### **Characteristics of the preparation**

The vaccine is protective antigens (hemagglutinin and neuraminidase) of epidemically actual strains of subtypes A (H<sub>1</sub>N<sub>1</sub>), A(H<sub>3</sub>N<sub>2</sub>) of type A and type B Yamagata line and Victoria line influenza viruses, isolated from virus-containing chick-embryo allantoic fluid in combination with immunoadjuvant Polyoxidonium® (INN: Azoximer bromide).

The strain composition of vaccine is updated annually in accordance with epidemic situations and guidelines of WHO for the Northern hemisphere.

**Pharmacotherapeutic group:** MIBP-vaccine.

**ATC code:**J07BB02.

### **Immunological properties**

The vaccine induces formation of high level of specific immune response against influenza. The protective effect post vaccination generally develops after 8-12 days and preserves till 12 months.

Addition of immunoadjuvant Polyoxidonium® with wide range of immunopharmacological action into the vaccine, ensures increased immunogenicity and antigen stability, allows to increase immunologic memory, to decrease substantially antigen vaccine dose.

### **Indications for use**

Specific influenza prophylaxis in children over 6 years of age, adolescents and adults under 60 years of age.

The preservative-free vaccine is used to immunize children from 6 to 18 years of age.

Vaccine is specifically indicated to:

#### *1. Individuals at high risk for influenza-associated complications:*

- individuals, who frequently ill with ARD, suffering chronic somatic diseases, including: diseases and congenital anomalies of central nervous system, cardiovascular and broncho-pulmonary system, bronchial asthma, chronic kidney diseases, diabetes mellitus, metabolic diseases, autoimmune diseases, allergic diseases (except for allergy to chicken proteins); chronic anemia, hereditary or acquired immunodeficiency, HIV-associated;

#### *2. Individuals with high occupational risk of influenza infection or influenza contamination of other individuals:*

medical staff, citizens who are subject to call-up for military service, employees of educational institutions, social service sphere, transport, trade, police, individuals, engaged in poultry industry, members of the military etc.

### **Contraindications**

- Allergic reaction to chicken protein and vaccinal components, including thiomersal, contained in multidose vials.
- Allergic reactions to previously administered influenza vaccines.

- Strong reaction (temperature is above 40 °C, edema and hyperemia at injection site over 8 cm in diameter) or history of complications to previous administration of influenza vaccines.

Acute infectious or non-infectious diseases, exacerbations of chronic diseases - vaccinations are performed 2-4 weeks after recovery or during convalescence or remission period.

- In non-severe ARVI, acute intestinal diseases the vaccination is performed after normalization of temperature.

- Children aged below 6 years.

- Age below 18 years (using the vaccine, containing preservative thiomersal).

- Pregnancy (using the vaccine, containing preservative thiomersal).

### **With caution**

Not for intravenous injection!

Antishock medicinal products should be envisaged in rooms, where vaccination is performed.

A vaccinated person should be under follow-up with healthcare provider for 30 min post immunization.

### **Use during pregnancy and lactation**

The decision concerning immunization of pregnant women should be taken individually by a physician considering a risk of influenza infection and possible complications of influenza infection. The immunization is most safe at the second and third trimester.

Breastfeeding is not a contraindication for immunization.

### **Dosage and Administration**

The vaccination is performed annually in the autumn-winter period. The vaccination is possible at the beginning of epidemic raise of flu morbidity.

The vaccine is administered intramuscularly or deep subcutaneously in the upper third of external surface of the upper arm (into the deltoid).

Dosage for children from 6 years of age, adolescents and adults: 0.5 ml given as a single dose.

*For patients with immunodeficiency and those receiving immunosuppressive therapy* the administration of vaccine in two doses 0.5 ml with 3-4-week interval is possible.

The vaccine should be kept till room temperature and mix well before use.

Using a syringe it is necessary to take off a protective cap from the needle and remove the air out of syringe, holding it in the vertical position with the needle upwards and slowly pressing to a plunger.

The opening of multidose vial is executed in strict compliance with aseptic and antiseptic regulations. Ahead of opening of a vial wipe out the external surface of its stopper with cotton wool, soaked with 70% alcohol, withdraw the vaccine into a disposable syringe and remove the air excess out of the syringe. A new sterile syringe with a new sterile needle should be used for each collected dose for each patient. Within the intervals between collections of doses and not later than 5 min after the last collection, it is necessary to place the vial into a fridge (but not into a freezer) for storage at temperature 2 to 8 °C. The medicinal product in opened multidose vial may be used within a working day in compliance of appropriate storage conditions.

It is necessary to immediately dispose a partially utilised multidose vial in cases as follows:

- if it is impossible to assure sterility of withdraw of the vaccine;
- probable or actual contamination;
- change of appearance and presence of impurities.

The vaccine in multidose vial should be kept for all storage period in accordance with manufacture's recommendations, specified in patient information leaflet. After use all residues of the vaccine and package should be disposed using safe method in according to local regulations.

### **Adverse effects**

The vaccine is a highly purified product and well-tolerated.

The rate of adverse events, registered during conduction of clinical trials, is presented in accordance with the ADR WHO classification.

The rate of adverse events across the WHO classification: very frequent (>1/10), frequent (>1/100 and <1/10), infrequent (>1/1000 and <1/100), rare (>1/10000 and <1/1000), very rare (<1/10000).

Blood and lymphatic system disorders: rare - increased lymph nodes.

Nervous system disorders: frequent - head ache.

Respiratory, thoracic and mediastinum-related disorders: frequent - runny nose, throat hyperemia, infrequent - sore throat.

Musculoskeletal and connective tissue disorders: infrequent - myalgia, arthralgia.

General disorders and administration site conditions:

- general disorders: frequent - malaise;

- administration site conditions: very frequent - pain, redness, formation of indurations (infiltration) and swelling at administration site, frequent - itch at administration site.

Investigations: infrequent - increased body temperature.

Most reactions are generally resolved spontaneously within 2-3 days.

Although there are no clinical findings, it is impossible to eliminate the possibility of the development of neurological disorders and allergic reactions (including immediate reactions, to chicken protein and other vaccinal components) characteristic for influenza vaccines.

Patient should be informed that it is necessary to report his/her physician on any apparent or not specified in this instruction adverse events.

### **Overdosage**

No case of overdoses registered.

### **Interactions**

Grippol® Quadrivalent vaccine against influenza quadrivalent inactivated subunit adjuvant may be administered concomitantly with inactivated and live vaccines according to National Immunization Schedule (excluding BCG and BCG-M) and inactivated vaccines from Immunization Schedule by epidemic indications (excluding antirabic vaccines). However contraindications to each of the used vaccine should be taken into account; the medicinal products should be administered in different parts of the body using different syringes.

The vaccine should be administered on basis therapy, available in vaccinated disease. The immunization of patients, receiving immunosuppressive therapy (glucocorticosteroids, cytostatic preparations, radiotherapy) may be less effective.

### **Special precautions**

On day of vaccination the individuals being vaccinated should be examined by a physician (physician assistant) with compulsory thermometry. The vaccination is not performed at temperature over 37.0 °C

The medicinal product in syringes with disturbed integrity and labeling, with changed physical

properties (color, clarity), with expired date, impaired requirements for storage is not suitable for use. The inobservance of technique of collection of doses out of multidose vial may reflect in properties of the medicinal product. Therefore the manufacturer is responsible for its quality for 24 hours after the first procedure of collection only at storage condition in fridge in accordance with manufacturer's guidelines.

Multidose vials Grippol® Quadrivalent contain small quantity of thiomersal as a preservative, which may be a reason of allergic reaction.

#### **Effect on ability to drive and use machines**

Grippol® Quadrivalent vaccine against influenza quadrivalent inactivated subunit adjuvant causes no effect of ability to drive and use machines.

#### **Presentation**

Solution for intramuscular and subcutaneous injection.

0.5 ml (1 dose) into glass disposable syringes.

5.0 ml (10 doses) with preservative into glass vials, sealed with rubber stoppers and capped with aluminum crimps.

1, 5 or 10 syringes in PVC blister pack, covered with aluminium foil with polymer coating.

1 (containing 1 or 5 syringes or 10 syringes) or 2 (containing 5 syringes) blister packs in carton box together with patient information leaflet.

1 vial in carton box together with patient information leaflet.

10, 20 or 50 vials in carton box with carton insert together with patient information leaflet.

#### **Storage conditions**

Protected from light at 2 °C to 8 °C. Do not freeze. Frozen preparation cannot be used.

Keep out of the reach of children.

#### **Transportation conditions**

Protected from light at 2 °C to 8 °C. Do not freeze. Transportation at temperature below 25 °C for maximum 24 hours is allowed.

#### **Shelf life**

1 year. Do not use after expiry date.

#### **Purchasing terms**

Package, containing 1 syringe, is available on prescription.

Package, containing 5 or 10 syringes, 1, 10, 20 or 50 vials is dispensed for healthcare centres.

#### **Manufacturer / Marketing authorisation holder**

NPO Petrovax Pharm LLC

Russia, 142143, Moscow Region, Podolsk, Pokrov village, Sosnovaya street, 1,

tel./fax: +7 (495) 926-21-07,

e-mail: info@petrovax.ru;

#### **Consumer complaints organization**

NPO Petrovax Pharm LLC

Russia, 142143, Moscow Region, Podolsk, Pokrov village, Sosnovaya street, 1,

tel.: +7(495) 730-75-45, 8 800 234-44-80,

e-mail: [adr@petrovax.ru](mailto:adr@petrovax.ru)

Send reclamations on medicinal product quality concerning physical properties, package and information about the cases of increased reactogenicity or cases of postvaccinal complications development with obligatory indication of batch number and date of manufacture and subsequent provision of medicinal documentation to the manufacturer NPO Petrovax Pharm, LLC and to the Federal Service for Surveillance in Healthcare (Roszdravnadzor).